Specific protection against breast cancers by cyclin D1 ablation
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“genetically engineered mouse models clearly revealed the importance of cyclin D1-CDK4 activity for the initiation and maintenance of HER2-driven breast cancers (98-100)”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [98]
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
β-Catenin regulates expression of cyclin D1 in colon carcinoma cells
Tetsu, O., & McCormick, F. (1999) · Nature · doi:10.1038/18884 · Cited by 3,601
Cyclin D1 Expression Is Regulated Positively by the p42/p44 and Negatively by the p38/HOG Pathway
Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R., & Pouysségur, J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.34.20608 · Cited by 1,211 · cited 1×
“Discussion The ras oncogene, acting through the mitogen-activated protein kinase pathway, is known to induce cyclin D1 by acting on cyclin D1 promote”
BackgroundMuller, W. J., Sinn, E., Pattengale, P. K., Wallace, R., & Leder, P. (1988) · Cell · doi:10.1016/0092-8674(88)90184-5 · Cited by 1,165
Cyclin D1 provides a link between development and oncogenesis in the retina and breast
Sicinski, P., Donaher, J. L., Parker, S. B., Li, T., Fazeli, A., Gardner, H., Haslam, S. Z., Bronson, R. T., Elledge, S. J., & Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90034-9 · Cited by 1,021
Bargmann, C. I., Hung, M.-C., & Weinberg, R. A. (1986) · Cell · doi:10.1016/0092-8674(86)90779-8 · Cited by 1,006
Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice
Wang, T. C., Cardiff, R. D., Zukerberg, L., Lees, E., Arnold, A., & Schmidt, E. V. (1994) · Nature · doi:10.1038/369669a0 · Cited by 965
Spontaneous mammary adenocarcinomas in transgenic mice that carry and express MTV/myc fusion genes
Stewart, T. A., Pattengale, P. K., & Leder, P. (1984) · Cell · doi:10.1016/0092-8674(84)90257-5 · Cited by 899
Transforming p21 Mutants and c-Ets-2 Activate the Cyclin D1 Promoter through Distinguishable Regions
Albanese, C., Johnson, J., Watanabe, G., Eklund, N., Vu, D., Arnold, A., & Pestell, R. G. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.40.23589 · Cited by 803
Sinn, E., Muller, W., Pattengale, P., Tepler, I., Wallace, R., & Leder, P. (1987) · Cell · doi:10.1016/0092-8674(87)90449-1 · Cited by 792
Cited by
Items 401–500 of 937
Butt, A. J., Caldon, C. E., McNeil, C. M., Swarbrick, A., Musgrove, E. A., & Sutherland, R. L. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-0-387-78818-0_12 · Cited by 59
PPM1H Is a p27 Phosphatase Implicated in Trastuzumab Resistance
Lee-Hoeflich, S. T., Pham, T. Q., Dowbenko, D., Munroe, X., Lee, J., Li, L., Zhou, W., Haverty, P. M., Pujara, K., Stinson, J., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0062 · Cited by 62
Progress with palbociclib in breast cancer: latest evidence and clinical considerations
Rocca, A., Schirone, A., Maltoni, R., Bravaccini, S., Cecconetto, L., Farolfi, A., Bronte, G., & Andreis, D. (2016) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834016677961 · Cited by 69
Kilker, R. L., Hartl, M. W., Rutherford, T. M., & Planas-Silva, M. D. (2004) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2004.05.005 · Cited by 59
Xie, Y., Skytting, B., Nilsson, G. P., Gasbarri, A., Haslam, K., Bartolazzi, A., Brodin, B. A., Mandahl, N., & Larsson, O. (2002) · PubMed · Cited by 59
Wu, K., Wang, C., D’Amico, M., Lee, R. J., Albanese, C., Pestell, R. G., & Mani, S. (2002) · PubMed · Cited by 71
Landis, M. D., Seachrist, D. D., Montanez-Wiscovich, M. E., Danielpour, D., & Keri, R. A. (2005) · Oncogene · doi:10.1038/sj.onc.1208712 · Cited by 58
“…excellent tool for deciphering the molecular pathways responsible for ErbB2/Neu-induced tumorigenesis and identifying novel targets for both chemoprevention and chemotherapy (Li et al., 1997; Boggio et al., 1998; Lenferink et al., 2000; Shepherd et al., 2001; Yu et al., 2001; Bulavin et al., 2004).”
MethodDifferential effects of progestogens on breast cancer cell lines
Franke, H. R., & Vermes, I. (2003) · Maturitas · doi:10.1016/j.maturitas.2003.09.019 · Cited by 58
“It has been demonstrated that mice lacking Cyclin D1 are resistant to breast cancers induced by the neu and ras oncogenes, both known as acting through the mitogen-activated protein kinase pathway, which is important for the estrogen action in breast cancer cells [17].”
BackgroundThe fabric of cancer cell biology—Weaving together the strands
Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00020-x · Cited by 57
Hwang, S. J., Lee, H. W., Kim, H. R., Song, H. J., Lee, D. H., Lee, H., Shin, C. H., Joung, J.-G., Kim, D.-H., Joo, K. M., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.3886 · Cited by 58
“Several oncogenes such as HER2 and Ras activate the cyclin D1 promoter, and silencing of cyclin D1 inhibits their oncogenic signaling [17].”
BackgroundCancer therapy based on oncogene addiction
McCormick, F. (2011) · Journal of Surgical Oncology · doi:10.1002/jso.21749 · Cited by 57
“Using this approach, it has been shown that cyclin D1 [13], TIAM-1 [14] RalGDS [15], NFkB [16] are necessary for Ras-induced cancers in mice.”
MethodLong noncoding RNA CASC9.5 promotes the proliferation and metastasis of lung adenocarcinoma
Zhou, J. J., Xiao, H., Yang, X., Tian, H., Xu, Z., Zhong, Y., Ma, L., Zhang, W., Qiao, G., & Liang, J. (2018) · Scientific Reports · doi:10.1038/s41598-017-18280-3 · Cited by 62
Pan, M., Lin, C., Tsai, J., Ho, C., & Chen, W. J. (2009) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf903067g · Cited by 56
Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer
Wu, Y., Zhang, Y., Pi, H., & Sheng, Y. (2020) · Cancer Management and Research · doi:10.2147/cmar.s250632 · Cited by 60
Barabutis, N., Tsellou, E., Schally, A. V., Kouloheri, S., Kalofoutis, A., & Kiaris, H. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700407104 · Cited by 56
van der Horst, E. H., Murgia, M., Treder, M., & Ullrich, A. (2005) · International Journal of Cancer · doi:10.1002/ijc.20867 · Cited by 59
“50 Cyclin D1 is overexpressed in >50% of diagnosed breast carcinomas and has a causative role in the pathogenesis of breast cancer induced by neu, the oncogenic variant of HER2.”
InfluentialJiang, Z., & Zacksenhaus, E. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200106084 · Cited by 55
“In contrast to the MMTV/WAP-Rb K transgenic mice, cyclin D1–deficient mice do not succumb to mammary tumors but are rather protected from a subset of oncogenic pathways in the mammary gland (Sicinski et al., 1995; Yu et al., 2001b).”
BackgroundResultThe two faces of Janus kinases and their respective STATs in mammary gland development and cancer
Wagner, K., & Schmidt, J. W. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.90677 · Cited by 62
“[93,94] Cyclin D1 is one of the downstream targets of Stat5 that might link PRL signaling to the cell cycle machinery,[48,95] and it has been suggested that lack of this cell cycle regulator protects against the onset of ErbB2and Myc-induced mammary tumorigenesis.[96] While the outcome of these experiments might sugge…”
BackgroundMyc is required for β-catenin-mediated mammary stem cell amplification and tumorigenesis
Moumen, M., Chiche, A., Decraene, C., Petit, V., Gandarillas, A., Deugnier, M., Glukhova, M. A., & Faraldo, M. M. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-132 · Cited by 58
“This result is in agreement with previous studies reporting that Cyclin D1 is dispensable for Wnt or β-catenin induced tumorigenesis [37,38].”
ResultAldoss, I. T., Tashi, T., & Ganti, A. K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903418445 · Cited by 56
“Another possibility may be that cancers may exhibit a differential dependency on the CDKs which may be related to the mutations present in that tumor; for example, animal models suggest that inhibition of cyclin D1 prevents breast cancer driven by ErbB2 and Hras oncogenes, but has decreased effect on cancers controlle…”
BackgroundCyclin D1 as a target for chemoprevention
Petty, W. J., Dragnev, K. H., & Dmitrovsky, E. (2003) · Lung Cancer · doi:10.1016/s0169-5002(03)00159-4 · Cited by 58
“[10] Yu Q, Geng Y, Sicinski P.”
BackgroundChen, L., Chen, J., & Xu, H. (2012) · Fitoterapia · doi:10.1016/j.fitote.2012.11.009 · Cited by 56
“Aside from being a critical regulator essential for G1 phase progression [29], cyclin D1 seems to have a causative role in breast cancer formation [30].”
BackgroundZhang, Q., Sakamoto, K., & Wagner, K. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.03.016 · Cited by 60
Zhang, Y. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107677 · Cited by 63
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Jhaveri, K. L., Burris, H. A., Yap, T. A., Hamilton, E. P., Rugo, H. S., Goldman, J. W., Dann, S. G., Liu, F., Wong, G. Y., Krupka, H. I., et al. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1944109 · Cited by 61
“In mouse models of HER2/neudriven mammary carcinoma, disease can be prevented by ablation of CCND1 or CDK4 [134].”
Takaoka, M., Harada, H., Deramaudt, T. B., Oyama, K., Andl, C. D., Johnstone, C. N., Rhoades, B., Enders, G. H., Opitz, O. G., & Nakagawa, H. (2004) · Oncogene · doi:10.1038/sj.onc.1207923 · Cited by 63
“Also, cyclin D1 is required for transformation by Ras of certain rodent epithelial cell types (Yu et al., 2001).”
BackgroundArctiin induces cell growth inhibition through the down-regulation of cyclin D1 expression
Matsuzaki, Y., Koyama, M., Hitomi, T., Yokota, T., Kawanaka, M., Nishikawa, A., Germain, D., & Sakai, T. (2008) · Oncology Reports · doi:10.3892/or.19.3.721 · Cited by 53
Dai, M., Boudreault, J., Wang, N., Poulet, S., Daliah, G., Yan, G., Moamer, A., Burgos, S. A., Sabri, S., Ali, S., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2121 · Cited by 57
Notch1-Induced Transformation of RKE-1 Cells Requires Up-regulation of Cyclin D1
Stahl, M. C., Ge, C., Shi, S., Pestell, R. G., & Stanley, P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0974 · Cited by 57
Mammary Development and Breast Cancer: The Role of Stem Cells
Ercan, C., van Diest, P. J., & Vooijs, M. (2011) · Current Molecular Medicine · doi:10.2174/156652411795678007 · Cited by 68
“Mice lacking the cyclinD1 gene have defects in hormone-induced proliferation during pregnancy [138] and are protected from breast cancer [139].”
BackgroundCyclin D2 and p27 Are Tissue-Specific Regulators of Tumorigenesis in Inhibin α Knockout Mice
Burns, K. H., Agno, J. E., Sicinski, P., & Matzuk, M. M. (2003) · Molecular Endocrinology · doi:10.1210/me.2003-0038 · Cited by 53
Tashiro, E., Maruki, H., Minato, Y., Doki, Y., Weinstein, I. B., & Imoto, M. (2003) · PubMed · Cited by 62
Transforming Growth Factor α–Dependent Cancer Progression Is Modulated by Muc1
Pochampalli, M. R., Bitler, B. G., & Schroeder, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4518 · Cited by 52
Yu, W., Lü, W., Chen, G., Cheng, F., Su, H., Chen, Y., Liu, M., & Pang, X. (2017) · British Journal of Pharmacology · doi:10.1111/bph.13961 · Cited by 54
“It has been reported that Cyclin D1 and E2F3 are essential components in the HER2/RAS oncogenic pathway (Wu et al., 2015; Yu et al., 2001), and down-regulation of Cyclin D1 and E2F3 leads to significant delay of mammary tumour onset (Wu et al., 2015; Yu et al., 2001).”
BackgroundChoi, J., Ryu, J., Bae, W., Park, A., Nam, S., Kim, J., & Jeong, J. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092832 · Cited by 52
“Cyclin D1 belongs to the family of D-type cyclins (cyclins D1, D2, and D3) and is expressed in an overlapping, redundant manner in all proliferating cells [31].”
BackgroundRole of cyclin D1 in ErbB2-positive breast cancer and tamoxifen resistance
Waltersson, M. A., Nordenskjöld, B. A., Rutqvist, L. E., Skoog, L. K., & Stål, O. (2005) · Breast Cancer Research and Treatment · doi:10.1007/s10549-004-6457-4 · Cited by 52
“Similar results were found in studies on mice where ErbB2 driven transformation of mammary glands was dependent on cyclin D1 to function [10, 11].”
BackgroundResultSomatic cell type specific gene transfer reveals a tumor-promoting function for p21Waf1/Cip1
Liu, Y., Yeh, N., Zhu, X.-H., Leversha, M., Cordon-Cardo, C., Ghossein, R., Singh, B., Holland, E., & Koff, A. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601886 · Cited by 52
“For example, it is difficult to reconcile the suggestion that p21 supports cyclin D–cdk4 accumulation in the MMTV-Wnt1 model, when Yu et al (2001) later demonstrated that cyclin D1 was not required in this model.”
BackgroundMethodShillingford, J. M., Miyoshi, K., Robinson, G. W., Bierie, B., Cao, Y., Karin, M., & Hennighausen, L. G. (2003) · Journal of Histochemistry & Cytochemistry · doi:10.1177/002215540305100501 · Cited by 56
“…rescue of both the lactation phenotype and Npt2b protein expression in IKK AA/AA mice by re-establishment of the cyclin D1 levels points to a role for cyclin D1 in mammary epithelial cell differentiation, in addition to its established role in mammary epithelial cell proliferation (Yu et al. 2001).”
BackgroundTargeting carcinogenesis: A role for the prolyl isomerase Pin1?
Lu, K. P., Suizu, F., Zhou, X. Z., Finn, G., Lam, P. B., & Wulf, G. M. (2006) · Molecular Carcinogenesis · doi:10.1002/mc.20216 · Cited by 52
Recent advances in inducible expression in transgenic mice
Albanese, C., Hulit, J., Sakamaki, T., & Pestell, R. G. (2002) · Seminars in Cell and Developmental Biology · doi:10.1016/s1084-9521(02)00021-6 · Cited by 58
New Approaches to Target T-ALL
Roti, G., & Stegmaier, K. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00170 · Cited by 57
Wang, C., Tai, Y., Lisanti, M. P., & Liao, D. J. (2011) · Cancer Biology & Therapy · doi:10.4161/cbt.11.7.14688 · Cited by 59
Dalvai, M., & Bystricky, K. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011011 · Cited by 61
“Its overexpression in mice leads to development of mammary carcinoma, while down-regulation induces resistance to cancer development [35,36].”
BackgroundWSB1 overcomes oncogene-induced senescence by targeting ATM for degradation
Kim, J. J., Lee, S. B., Yi, S. Y., Han, S.-A., Kim, S., Lee, J., Tong, S., Yin, P., Gao, B., Zhang, J., et al. (2016) · Cell Research · doi:10.1038/cr.2016.148 · Cited by 58
ErbB2 down-regulates microRNA-205 in breast cancer
Adachi, R., Horiuchi, S., Sakurazawa, Y., Hasegawa, T., Sato, K., & Sakamaki, T. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.033 · Cited by 58
Palbociclib for Hormone-Receptor–Positive, HER2-Positive Advanced Breast Cancer
Metzger, O., Mandrekar, S. J., Goel, S., Gligorov, J., Lim, E., Ciruelos, E., Loibl, S., Dockter, T., González, X., Francis, P. A., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2511218 · Cited by 62
LMO4 is an essential mediator of ErbB2/HER2/Neu-induced breast cancer cell cycle progression
Montañez-Wiscovich, M. E., Seachrist, D. D., Landis, M. D., Visvader, J. E., D, B. A. M., & Keri, R. A. (2009) · Oncogene · doi:10.1038/onc.2009.221 · Cited by 52
“These pathways induce proliferation, in part by upregulating the cell cycle protein, Cyclin D1 (Lenferink et al., 2001), which is essential for ErbB2-induced transformation (Yu et al., 2001; Lee et al., 2000).”
BackgroundPatel, P. M., Asbach, B., Shteyn, E., Gomez, C., Coltoff, A. R., Bhuyan, S., Tyner, A. L., Wagner, R., & Blain, S. W. (2015) · Molecular and Cellular Biology · doi:10.1128/mcb.01206-14 · Cited by 57
Mouse models of estrogen receptor-positive breast cancer
Band, V., Mirza, S., Mohibi, S., & Band, H. (2011) · Journal of Carcinogenesis · doi:10.4103/1477-3163.91116 · Cited by 61
“[81-82] Researchers have demonstrated that cyclin D1 is essential for the development of mouse mammary cancers induced by c-neu and v-Ha-ras, but not those induced by c-myc or Wnt-1.”
BackgroundCDK4/6 inhibitors in HER2-positive breast cancer
Corona, S. P., Ravelli, A., Cretella, D., Cappelletti, M. R., Zanotti, L., Dester, M., Gobbi, A., Petronini, P. G., & Generali, D. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.02.022 · Cited by 53
Tannapfel, A., John, K., Mise, N., Schmidt, A., Buhlmann, S., Ibrahim, S. M., & Pützer, B. M. (2007) · Carcinogenesis · doi:10.1093/carcin/bgm236 · Cited by 58
Sakamoto, K., Schmidt, J. W., & Wagner, K. (2015) · Methods in molecular biology · doi:10.1007/978-1-4939-2297-0_3 · Cited by 49
“[31] that deficiency in Cyclin D1 protects against ErbB2induced breast cancer has recently been challenged [32].”
BackgroundCDK4/6 inhibitors in breast cancer
Dukelow, T., Kishan, D., Khasraw, M., & Murphy, C. G. (2015) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000249 · Cited by 54
Mosley, J. D., Poirier, J. T., Seachrist, D. D., Landis, M. D., & Keri, R. A. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0235 · Cited by 48
“Phosphorylation of 4EBP1 induces its dissociation from eIF-4E, which enhances cap-dependent translation of numerous mRNAs including cell cycle regulators such as cyclin D1, an essential regulator of proliferation in HER2/ErbB2 cells (7, 8).”
BackgroundCDK4/6 inhibitors in breast cancer: beyond hormone receptor-positive HER2-negative disease
Matutino, A. R. B., Amaro, C. P., & Verma, S. (2018) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835918818346 · Cited by 52
Marcotte, R., & Muller, W. J. (2008) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1007/s10911-008-9087-3 · Cited by 54
“Alternatively, loss of Cyclin D1 completely abrogated tumor development in MMTV-Ras and MMTVNeu mice, but had no effect on tumor onset in MMTV-Myc or MMTV-Wnt1 mice, suggesting that Cyclin D1 is a key mediator of the Ras-Neu transformation pathway [83].”
BackgroundCyclin D1 gene polymorphism as a risk factor for oral premalignant lesions
Huang, M. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl048 · Cited by 48
Weiss, R. H., Marshall, D., Howard, L. L., Corbacho, A. M., Cheung, A., & Sawai, E. T. (2002) · Cancer Letters · doi:10.1016/s0304-3835(02)00495-0 · Cited by 52
Nahta, R., Iglehart, J. D., Kempkes, B., & Schmidt, E. V. (2002) · PubMed · Cited by 48
CDK4/6 and MAPK—Crosstalk as Opportunity for Cancer Treatment
Scheiblecker, L., Kollmann, K., & Sexl, V. (2020) · Pharmaceuticals · doi:10.3390/ph13120418 · Cited by 55
“Ras has long been considered undruggable, due to the absence of any deep hydrophobic pocket on its surface that could serve as a binding site for a small molecular inhibitor [33,120].”
BackgroundInfluentialApoptosis, proliferation, differentiation: in search of the order
Blagosklonny, M. V. (2003) · Seminars in Cancer Biology · doi:10.1016/s1044-579x(02)00127-x · Cited by 52
Combined Treatment of γ-Tocotrienol with Statins Induce Mammary Tumor Cell Cycle Arrest in G1
Wali, V. B., Bachawal, S. V., & Sylvester, P. W. (2009) · Experimental Biology and Medicine · doi:10.3181/0810-rm-300 · Cited by 54
“In addition, cyclin D1 knockout mice are resistant to HER2 and Ras induced tumorigenesis (37, 38).”
BackgroundMazurek, N., Sun, Y. J., Price, J. E., Ramdas, L., Schober, W. D., Nangia‐Makker, P., Byrd, J. C., Raz, A., & Bresalier, R. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3333 · Cited by 47
“Cyclin D1 is overexpressed in f50% of all breast cancers and its role in tumor progression is well established (42).”
BackgroundDissecting the roles of β-catenin and cyclin D1 during mammary development and neoplasia
Rowlands, T. M., Pechenkina, I. V., Hatsell, S. J., Pestell, R. G., & Cowin, P. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1534601100 · Cited by 58
NFκB-mediated cyclin D1 expression by microRNA-21 influences renal cancer cell proliferation
Bera, A., Ghosh‐Choudhury, N., Dey, N., Das, F., Kasinath, B. S., Abboud, H. E., & Choudhury, G. G. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2013.08.005 · Cited by 48
Loomis, K. D., Zhu, S., Yoon, K., Johnson, P. F., & Smart, R. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0139 · Cited by 54
“Moreover, cyclin D1 or CDK4 deficiency results in decreased Ras-induced tumorigenesis (55, 56), whereas increased”
BackgroundLi, Q., Ran, P., Zhang, X., Guo, X., Yuan, Y., Dong, T., Zhu, B. L., Zheng, S., & Xiao, C. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000494482 · Cited by 46
Carrascosa, C., Obula, R. G., Missiaglia, E., Lehr, H., Delorenzi, M., Frattini, M., Rüegg, C., & Mariotti, A. (2011) · Oncogene · doi:10.1038/onc.2011.356 · Cited by 46
“In contrast, its ablation in transgenic mice expressing Neu or ras oncogenes prevents mammary carcinoma development (Yu et al., 2001).”
BackgroundHypoxia activates the cyclin D1 promoter via the Jak2/STAT5b pathway in breast cancer cells
Joung, Y. H., Lim, E. J., Lee, M. Y., Park, J., Ye, S., Park, E. U., Kim, S. Y., Zhang, Z., Lee, K. J., Park, D. K., et al. (2005) · Experimental & Molecular Medicine · doi:10.1038/emm.2005.45 · Cited by 51
“However, overexpression of cyclin D1, as is seen in approximately 50% of human mammary tumors (Bartkova et al., 1994; Yu et al., 2001), leads to mitogenesis in mammary tumor cells in culture (Musgrove et al., 1994; Kim et al., 2003).”
BackgroundHewitt, S. C., Bocchinfuso, W. P., Zhai, J. L., Harrell, C., Koonce, L., Clark, J., Myers, P., & Korach, K. S. (2002) · PubMed · Cited by 58
Sicinska, E., Lee, Y.-M., Gits, J., Shigematsu, H., Yu, Q., Rebel, V. I., Geng, Y., Marshall, C. J., Akashi, K., Dorfman, D. M., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00800-06 · Cited by 45
“Northern blot analyses were performed as described previously (32, 39).”
BackgroundMethodSelf-citationGerson‐Gurwitz, A., Young, N. P., Goel, V., Eam, B., Stumpf, C. R., Chen, J. W., Fish, S., Barrera, M., Sung, E., Staunton, J., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.766298 · Cited by 51
“The protein level of cyclin D1 was also monitored as a marker for zotatifin activity as well as an additional measure of effects on cancer cell proliferation (28, 29).”
BackgroundCyclin‐dependent kinases: Masters of the eukaryotic universe
Pluta, A. J., Studniarek, C., Murphy, S., & Norbury, C. J. (2023) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1816 · Cited by 57
p27 kip1 controls H-Ras/MAPK activation and cell cycle entry via modulation of MT stability
Fabris, L., Berton, S., Pellizzari, I., Segatto, I., D’Andrea, S., Armenia, J., Bomben, R., Schiappacassi, M., Gattei, V., Philips, M. R., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508514112 · Cited by 51
“Cyclin D1 is transcribed following Ras-MAPK pathway activation, and the aberration of this molecular event underlies Ras-driven carcinogenesis (9, 10).”
BackgroundWip1 phosphatase in breast cancer
Emelyanov, A., & Bulavin, D. V. (2014) · Oncogene · doi:10.1038/onc.2014.375 · Cited by 49
The Role of the Cyclin D1-Dependent Kinases in ErbB2-Mediated Breast Cancer
Yang, C., Ionescu-Tiba, V., Burns, K. L., Gadd, M. A., Zukerberg, L. R., Louis, D. N., Sgroi, D. C., & Schmidt, E. V. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63190-2 · Cited by 48
“In murine models, intact cyclin D1 is required for mammary tumor formation in MMTV-erbB2 mice.(3) The known functions of cyclin D1 include: 1) its phosphorylation of the retinoblastoma gene product (pRb) mediated by its interaction with cyclin-dependent kinase 4/6 (Cdk 4/6);(4) 2) its interactions with several transcr…”
BackgroundCyclin degradation for cancer therapy and chemoprevention
Freemantle, S. J., Liu, X., Feng, Q., Galimberti, F., Blumen, S. R., Sekula, D., Kitareewan, S., Dragnev, K. H., & Dmitrovsky, E. (2007) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21519 · Cited by 46
“In this regard, mice lacking cyclin D1 are reported as resistant to breast cancers induced by MMTVdriven H-ras and c-neu/erbB-2 oncogenes [Yu et al., 2001].”
BackgroundSelection of extreme phenotypes: the role of clinical observation in translational research
Perez‐Gracia, J. L., Gúrpide, A., Ruiz-Ilundáin, M. G., Alegría, C. A., Colomer, R., García‐Foncillas, J., & Melero, I. (2010) · Clinical & Translational Oncology · doi:10.1007/s12094-010-0487-7 · Cited by 53
“Although these mice and other similar models [63,64] have been artificially developed, their relatively normal phenotypes raise the question of whether similar phenomena could spontaneously occur and be selected for in nature.”
BackgroundStaging of Breast Cancer in the Neoadjuvant Setting
Jeruss, J. S., Mittendorf, E. A., Tucker, S. L., Gonzalez-Angulo, A. M., Buchholz, T. A., Şahin, A. A., Cormier, J. N., Buzdar, A. U., Hortobágyi, G. N., & Hunt, K. K. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6520 · Cited by 45
“The loss of normal cell-cell interactions, high mitotic count, nuclear pleomorphism, and loss of normal hormone receptor expression have also been associated with cell cycle abnormalities, including overexpression of cyclins and down-regulation of cyclin-dependent kinase inhibitors (17, 18).”
Cho, E. Y., Choi, Y., Han, J. J., Kim, K., & Oh, Y. L. (2007) · Pathology International · doi:10.1111/j.1440-1827.2007.02183.x · Cited by 46
Zhang, J., Yang, Z., Li, P., Bledsoe, G., Chao, L., & Chao, J. (2013) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-013-1654-2 · Cited by 45
“Cyclin D1 is one of the cell cycle-regulating oncoproteins, playing a pivotal role not only in breast carcinogenesis, but also development of the mammary gland [32].”
Cyclin D1 Promotes Androgen-Dependent DNA Damage Repair in Prostate Cancer Cells
Casimiro, M. C., Sante, G. D., Ju, X., Li, Z., Chen, K., Crosariol, M., Yaman, İ., Gormley, M., Meng, H., Lisanti, M. P., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0999 · Cited by 48
“Journal of andrology 1998;19(6):718-24.”
BackgroundJiang, B., & Pei, D. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b00411 · Cited by 44
Thomas, A. L., Lind, H., Hong, A., Đokić, D., Oppat, K. M., Rosenthal, E., Guo, A., Thomas, A. J., Hamden, R., & Jeruss, J. S. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1338988 · Cited by 45
Cdk4 and Nek2 Signal Binucleation and Centrosome Amplification in a Her2+ Breast Cancer Model
Pitner, M. K., & Saavedra, H. I. (2013) · PLoS ONE · doi:10.1371/journal.pone.0065971 · Cited by 47
“Cyclin D1 and its catalytic partners Cdk4/Cdk6 have been shown to be required for Her2-induced transformation [41–44], but the mechanism driving this phenotype remains unknown.”
BackgroundPotential anticancer activity of the medicinal herb, Rhazya stricta, against human breast cancer
Nabih, A. B., Ayman, I. E., Osama, A. A., & Mohammed, H. M. (2012) · AFRICAN JOURNAL OF BIOTECHNOLOGY · doi:10.5897/ajb12.570 · Cited by 48
“…D1 is another central player in cell cycle, overexpressed in up to 50% of human breast cancers, acts as a driving force in human breast cancer (Arnold and Papanikolaou, 2005) and plays an essential role in malignant transformation of breast cancers induced by other oncogenes (Yu et al., 2001).”
BackgroundScotti, M. L., Langenheim, J. F., Tomblyn, S., Springs, A. E. B., & Chen, W. Y. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9789-z · Cited by 44
“The striking dependence of HER2 on cyclin D1 is highlighted by experiments in which the cyclin D1 gene was mutated [10], deleted [11], or a cyclin-dependent kinase inhibitor (p16) was overexpressed in MMTV-neu mice [12].”
BackgroundA Subtle Change in p38 MAPK Activity is Sufficient to Suppress In Vivo Tumorigenesis
Timofeev, O., Lee, T. Y., & Bulavin, D. V. (2005) · Cell Cycle · doi:10.4161/cc.4.1.1342 · Cited by 44
Lv, L., Zhou, Z., Huang, X., Zhao, Y., Zhang, L., Shi, Y., Sun, M., & Zhang, J. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0409-8 · Cited by 43
“More essentially, Pin1 regulates the function of cyclin D1, a pivotal protein in breast cancer pathogenosis [25], through multiple mechanisms [26].”
The LIM-only Protein FHL2 Regulates Cyclin D1 Expression and Cell Proliferation
Labalette, C., Nouët, Y., Sobczak‐Thépot, J., Armengol, C., Levillayer, F., Gendron, M., Renard, C.-A., Regnault, B., Chen, J., Buendia, M., et al. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m800708200 · Cited by 44
Stromal cyclin D1 promotes heterotypic immune signaling and breast cancer growth
Pestell, T. G., Jiao, X., Kumar, M., Peck, A. R., di Prisco, M., Deng, S., Li, Z., Ertel, A., Casimiro, M. C., Ju, X., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19953 · Cited by 44
“The abundance of cyclin D1 is rate limiting in the growth of tumors in vivo, including ErbB2-induced breast cancer [2, 3] and gastrointestinal tumorigenesis [4].”
BackgroundSudhan, D. R., Schwarz, L. J., Zotano, Á. G., Formisano, L., Nixon, M. J., Croessmann, S., Ericsson, P. I. G., Sanders, M. E., Balko, J. M., Avogadri-Connors, F., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1131 · Cited by 46
“Mousemammary glands deficient in cyclinD1are largely resistant to the tumor-initiating effects of ErbB2 (21, 22, 49).”
BackgroundLess-well known functions of cyclin/CDK complexes
Palmer, N., & Kaldis, P. (2020) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2020.04.003 · Cited by 51
The retinoblastoma protein—from bench to bedside
Mittnacht, S. (2005) · European Journal of Cell Biology · doi:10.1016/j.ejcb.2004.12.012 · Cited by 49
Cdk2-Null Mice Are Resistant to ErbB-2-Induced Mammary Tumorigenesis
Ray, D., Terao, Y., Christov, K. T., Kaldis, P., & Kiyokawa, H. (2011) · Neoplasia · doi:10.1593/neo.101704 · Cited by 46
“Cyclin D1, the major regulatory subunit for Cdk4, is also required for MMTVneu–induced mammary tumorigenesis [5].”
BackgroundGarcía‐España, A., Salazar, E., Sun, T., Wu, X., & Pellicer, À. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2074 · Cited by 44
“On the other hand, mice lacking the cyclin D1 gene have specific alterations in mammary epithelial proliferation (33, 34), most likely because cyclin D1 functions as an important mitogen and as a coactivator for the estrogen receptor (35).”
BackgroundAnsah, C., & Mensah, K. B. (2013) · PubMed · Cited by 42
LRH1 promotes pancreatic cancer metastasis
Lin, Q., Aihara, A., Chung, W., Li, Y., Chen, X., Huang, Z., Weng, S., Carlson, R. I., Nadolny, C., Wands, J. R., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.04.017 · Cited by 44
The role of a newly identified SET domain-containing protein, SETD3, in oncogenesis
Chen, Z., Yan, C. T., Dou, Y., Viboolsittiseri, S. S., & Wang, J. H. (2012) · Haematologica · doi:10.3324/haematol.2012.066977 · Cited by 45
“The amino-terminal tails of the core histones can be modified by post-translational modifications such as lysine (K) methylation (me), which is mediated by histone methyltransferases (HMTs) (2).”
BackgroundMeng, H., Tian, L., Zhou, J., Li, Z., Jiao, X., Li, W. W., Plomann, M., Xu, Z., Lisanti, M. P., Wang, C., et al. (2011) · Cell Cycle · doi:10.4161/cc.10.1.14243 · Cited by 42
“Gastrointestinal tumors induced by mutation of the Apc gene are reduced in number by cyclin D1 deficiency.12 Consistent with findings that the cyclin D1 antisense abrogates mammary epithelial cell growth induced by ErbB2,13 cyclin D1-deficient mice are resistant to mammary gland tumorigenesis induced by Ras or ErbB2.”
Metadata
- Authors
- Yu, Q., Geng, Y., & Sicinski, P.
- Affiliations
- Harvard University (US)
- ORCID
- Yu, Qunyan
- Venue
- Nature
- Published
- 2001-06
- Volume
- 411
- Issue
- 6841
- Pages
- 1017-1021
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2098953839
- Cited by
- 934
- References
- 31
- Citations by year
- 2026: 9 · 2025: 5 · 2024: 12 · 2023: 26 · 2022: 19 · 2021: 24 · 2020: 32 · 2019: 22 · 2018: 24 · 2017: 36 · 2016: 25 · 2015: 33 · 2014: 32 · 2013: 33 · 2012: 35
- FWCI
- 33.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- cyclin D1, breast cancer, neu oncogene, oncogenic Ras, cell cycle, mammary epithelium, malignant transformation, c-Myc, Wnt1, targeted cancer therapy
- MeSH terms
- Animals, Antineoplastic Agents, Breast, Breast Neoplasms, Cell Transformation, Neoplastic, Crosses, Genetic, Female, Humans, Male, Mammary Tumor Virus, Mouse, Mammary Neoplasms, Experimental, Proto-Oncogene Proteins, Genes, ras, Tumor Cells, Cultured, Genes, myc, Genes, erbB-2, Cyclin D1, Genes, bcl-1, Genetic Predisposition to Disease, Zebrafish Proteins, Animals, Genetically Modified, Wnt Proteins, Wnt1 Protein, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.